Employees: 3,069
Size Morepen Laboratories (MOREPENLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $542M, the 823rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹92.37 on 18 Nov 2026.
Performance Over six months the shares gained 120.7%, against -20.2% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 30.2% over the last twelve months (peer median -2.7%); the operating margin is 10.6% (peer median 6.4%).
Valuation It trades at 2.2× enterprise value to sales against a peer median of 5.6× (7th cheapest of 19).
Capital Return on invested capital runs 3.6 points below its cost of capital (16.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹22.9B | ₹18.0B | ₹18.1B | ₹16.8B | ₹14.1B |
| Revenue growth | — | 0% | +7% | +19% | — |
| Gross profit | ₹6.34B | ₹3.18B | ₹3.17B | ₹3.26B | ₹2.19B |
| EBITDA | ₹2.76B | ₹1.22B | ₹1.70B | ₹1.50B | ₹764M |
| Net income | ₹1.89B | ₹949M | ₹1.18B | ₹962M | ₹387M |
| Free cash flow | n/a | -₹693M | -₹1.00B | -₹117M | -₹1.39B |
| Capital expenditure | n/a | ₹2.04B | ₹2.38B | ₹813M | ₹460M |
| Total debt | ₹3.23B | ₹2.08B | ₹1.05B | ₹290M | ₹252M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOREPENLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.0% | -7.2% | 4th lowest of 20 |
| 6-month return | +120.7% | -20.2% | 2nd highest of 19 |
| Distance from 52-week high | -38.7% | -40.7% | 9th highest of 20 |
| Revenue growth (TTM) | +30.2% | -2.7% | 4th highest of 20 |
| Operating margin | 10.6% | 6.4% | 9th highest of 19 |
| EV / Sales | 2.2× | 5.6× | 7th cheapest of 19 |
| ROIC minus cost of capital | -3.6 pp | -1.0 pp | 7th lowest of 17 |
| EV / EBITDA | 18.5× | 7.7× | 3rd most expensive of 7 |
| Net debt / EBITDA | 0.2× | 0.3× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |